Shares of CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Zacks has also given CSPC Pharmaceutical Group an industry rank of 115 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised shares of CSPC Pharmaceutical Group from a “sell” rating to a “buy” rating and set a $82.00 price target for the company in a research note on Monday, October 9th.
COPYRIGHT VIOLATION NOTICE: “CSPC Pharmaceutical Group Ltd (CHPTY) Given Consensus Rating of “Strong Buy” by Brokerages” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2017/11/05/cspc-pharmaceutical-group-ltd-chpty-given-consensus-rating-of-strong-buy-by-brokerages.html.
Shares of CSPC Pharmaceutical Group (CHPTY) opened at $91.30 on Friday. CSPC Pharmaceutical Group has a 12 month low of $51.03 and a 12 month high of $91.80.
About CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about CSPC Pharmaceutical Group Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CSPC Pharmaceutical Group Ltd and related companies.